Clinical trials: Melanoma of Skin
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma (Skin Cancer), Artificial Intelligence (AI)
Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30).
- Conditions
- Melanoma (Skin Cancer), Artificial Intelligence (AI), Pediatric Cancer
- Trial name
- AI-MEL (NCT06621810)
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- German Cancer Research Center
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00055562
- Testing
- CC 5013
- Where
- 31 sites in United States, Canada
- Volunteers
- 274 people
- Sponsor
- Celgene Corporation
Melanoma (Skin)
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer.
- Trial name
- NCT00512889
- Testing
- therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Melanoma, Advanced Solid Tumors
AMT-253 in Patients With Advanced Solid Tumours
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors.
- Trial name
- NCT06209580
- Testing
- AMT-253 for injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Multitude Therapeutics Inc.
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Melanoma (Skin)
French Clinical Datbase of Melanoma Patients (RIC-Mel)
With a high incidence, low survival rates and limiter availability of effective treatment, melanoma is one of the research priorities for health authorities.
- Trial name
- RIC-Mel (NCT03315468)
- Where
- France
- Volunteers
- 16,000 people
- Sponsor
- Nantes University Hospital
Melanoma (Skin)
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398450
- Testing
- recombinant interferon alfa-2b, azacitidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Melanoma (Skin), Sarcoma
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy…
- Trial name
- NCT00004250
- Testing
- dactinomycin, isolated limb perfusion, melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
This is an open-label, phase II study of a vaccine comprising melanoma peptides and a tetanus helper peptide, administered in GM-CSF-in-adjuvant. Patients will be randomized to receive one of two different vaccine regimens.
- Trial name
- MEL39 (NCT00938223)
- Testing
- 4-peptide and 12-peptide melanoma vaccines
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
The study plans to treat patients with pembrolizumab and thus blocking the PD-1/PD-L1 axis would render tumor-infiltrating lymphocytes (TILs) in the tumor parenchyma more functional as a consequence of BRAF inhibition, such that…
- Trial name
- NCT02818023
- Testing
- Pembrolizumab, Vemurafenib, Cobimetinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yana Najjar
Skin Cancer, Non-Melanoma
Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients
Non-melanoma skin cancer (NMSC) incidence as well as morbidity rates are high in older patients. Surgery is the standard of care.
- Trial name
- IMPACTE-01 (NCT05794035)
- Testing
- Surgery with additional moderate hypofractionation RT (15 fractions), Surgery alone, without radiation post surgery, Surgery with extreme hypo fractionation treatment (HF)
- Where
- France
- Volunteers
- 303 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Melanoma, Stage IV Melanoma
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT01328535
- Testing
- temozolomide, flow cytometry, staining method
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Cutaneous Melanoma, Synovial Sarcoma
ACTengine® IMA203 Combined With mRNA-4203
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203.
- Trial name
- NCT06946225
- Testing
- IMA203, mRNA-4203
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Immatics US, Inc.
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
- Trial name
- NCT01904123
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Metastatic Melanoma
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
The purpose of this study is to evaluate the safety and efficacy of a sequential combination therapy of Nivolumab and Ipilimumab
- Trial name
- NCT01783938
- Testing
- Nivolumab, Ipilimumab
- Where
- 11 sites in United States
- Volunteers
- 138 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Malignant Melanoma
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
- Trial name
- PXS-X02 (NCT00235482)
- Testing
- Coxsackievirus A21
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Viralytics
Melanoma (Skin), Melanoma in Situ
Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm
The purpose of this study is to establish a standardized process for obtaining digital pathological image information of ocular tumors; use modern pathological techniques to obtain the co-expression information of multiple…
- Conditions
- Melanoma (Skin), Melanoma in Situ, Nevus Eye, Sebaceous Gland Carcinoma of the Eyelid
- Trial name
- NCT04695015
- Volunteers
- 100 people
- Sponsor
- Peking University
Melanoma
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
The purpose of this study is to compare the relapse free survival and overall survival of Imatinib (Gleevec) or high dose Interferon (Intron) in treating melanoma which has primary tumor and regional lymphonode (if have) removed…
- Trial name
- NCT01782508
- Testing
- imatinib, Interferon
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.